Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-17 | Mr. Bradbury is the founder and Managing Member of BioBrit, LLC, a life sciences consulting firm and investment fund. He has a Bachelor of Pharmacy and a Diploma in Management Studies. |
| 2014-04-07 | Mr. Bradbury has been CEO of Amylin Pharmaceuticals and serves on boards of life sciences companies; educational background in Pharmacy and Management Studies. |
| 2015-04-20 | He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. Our Board selected Mr. Bradbury to serve as a director because he brings to our Board extensive experience in operations and management in the pharmaceutical industry. |
| 2016-04-22 | Mr. Bradbury is founder and Managing Member of BioBrit, LLC, and has held executive roles in pharmaceutical companies. He holds a Bachelor of Pharmacy and a Diploma in Management Studies. |
| 2017-04-21 | Daniel M. Bradbury has served as a member of our Board since October 2012. Mr. Bradbury is the founder and Managing Member of BioBrit, LLC, a life sciences consulting firm and investment fund. Mr. Bradbury served as President and Chief Executive Officer of Amylin from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| 2018-04-24 | Daniel M. Bradbury has served as a member of our Board since October 2012. Mr. Bradbury is the Founder and Managing Member of BioBrit, LLC, a life sciences consulting and investment firm and Chief Executive Officer, Chairman and Co-Founder of Equillium, Inc., a private biopharmaceutical company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need. Mr. Bradbury served as President and Chief Executive Officer of Amylin from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-05 | Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders... He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies. |
| 2014-04-04 | Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| 2015-04-03 | Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders. |
| 2016-04-01 | He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| 2017-03-24 | Mr. Bradbury has served as a director of Geron since September 2012. He also serves as a director for Illumina, Inc., a manufacturer of life science tools and reagents, since January 2004; Corcept Therapeutics Incorporated, a company focused on the discovery and development of drugs; and Intercept Pharmaceuticals, Inc., a biopharmaceutical company. |
| 2018-03-30 | He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| 2019-04-22 | Mr. Bradbury held several senior positions at Amylin Pharmaceuticals and has a Bachelor of Pharmacy and a Diploma in Management Studies. |
Data sourced from SEC filings. Last updated: 2025-12-07